<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIPTANS-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIPTANS-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIPTANS-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
